Somatostatin binds to the human amyloid β peptide and favors the formation of distinct oligomers

Abstract

The amyloid β peptide (Aβ) is a key player in the etiology of Alzheimer disease (AD), yet a systematic investigation of its molecular interactions has not been reported. Here we identified by quantitative mass spectrometry proteins in human brain extract that bind to oligomeric Aβ1-42 (oAβ1-42) and/or monomeric Aβ1-42 (mAβ1-42) baits. Remarkably, the cyclic neuroendocrine peptide somatostatin-14 (SST14) was observed to be the most selectively enriched oAβ1-42 binder. The binding interface comprises a central tryptophan within SST14 and the N-terminus of Aβ1-42. The presence of SST14 inhibited Aβ aggregation and masked the ability of several antibodies to detect Aβ. Notably, Aβ1-42, but not Aβ1-40, formed in the presence of SST14 oligomeric assemblies of 50 to 60 kDa that were visualized by gel electrophoresis, nanoparticle tracking analysis and electron microscopy. These findings may be relevant for Aβ-directed diagnostics and may signify a role of SST14 in the etiology of AD.

Data availability

The following data sets were generated

Article and author information

Author details

  1. Hansen Wang

    Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
    Competing interests
    Hansen Wang, Holds provisionary US patent on amyloid-beta binding polypeptides based on the results of this study (filing number 62/451,309)..
  2. Lisa D Muiznieks

    Molecular Medicine Program, Research Institute, The Hospital for Sick Children, Toronto, Canada
    Competing interests
    No competing interests declared.
  3. Punam Ghosh

    Department of Medical Biophysics, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  4. Declan Williams

    Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  5. Michael Solarski

    Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  6. Andrew Fang

    Department of Biochemistry, University of Alberta, Edmonton, Canada
    Competing interests
    No competing interests declared.
  7. Alejandro Ruiz-Riquelme

    Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6581-7132
  8. Régis Pomès

    Molecular Medicine Program, Research Institute, The Hospital for Sick Children, Toronto, Canada
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3068-9833
  9. Joel C Watts

    Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  10. Avi Chakrabartty

    Department of Medical Biophysics, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  11. Holger Wille

    Department of Biochemistry, University of Alberta, Edmonton, Canada
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5102-8706
  12. Simon Sharpe

    Molecular Medicine Program, Research Institute, The Hospital for Sick Children, Toronto, Canada
    Competing interests
    No competing interests declared.
  13. Gerold Schmitt-Ulms

    Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada
    For correspondence
    g.schmittulms@utoronto.ca
    Competing interests
    Gerold Schmitt-Ulms, Holds provisionary US patent on amyloid-beta binding polypeptides based on the results of this study (filing number 62/451,309).
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6962-0919

Funding

Canadian Institutes of Health Research

  • Gerold Schmitt-Ulms

Ontario Centres for Excellence

  • Simon Sharpe
  • Gerold Schmitt-Ulms

Alberta Innovates Bio Solutions (201600028)

  • Holger Wille
  • Gerold Schmitt-Ulms

Heart and Stroke Foundation of Canada (G-15-0009148)

  • Simon Sharpe

Canada Foundation for Innovation

  • Gerold Schmitt-Ulms

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: The work was performed in strict accordance with University of Toronto animal care and biosafety recommendations. All mice were handled according to procedures approved (AUP4183.3) by the animal care committee at University Health Network overseeing work at the Krembil Discovery Centre (Toronto). The handling of samples and reagents followed biosafety procedures approved (208-S06-2) by the University of Toronto Biosafety Program.

Copyright

© 2017, Wang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,750
    views
  • 554
    downloads
  • 36
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Hansen Wang
  2. Lisa D Muiznieks
  3. Punam Ghosh
  4. Declan Williams
  5. Michael Solarski
  6. Andrew Fang
  7. Alejandro Ruiz-Riquelme
  8. Régis Pomès
  9. Joel C Watts
  10. Avi Chakrabartty
  11. Holger Wille
  12. Simon Sharpe
  13. Gerold Schmitt-Ulms
(2017)
Somatostatin binds to the human amyloid β peptide and favors the formation of distinct oligomers
eLife 6:e28401.
https://doi.org/10.7554/eLife.28401

Share this article

https://doi.org/10.7554/eLife.28401

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Jie Luo, Jeff Ranish
    Tools and Resources

    Dynamic conformational and structural changes in proteins and protein complexes play a central and ubiquitous role in the regulation of protein function, yet it is very challenging to study these changes, especially for large protein complexes, under physiological conditions. Here, we introduce a novel isobaric crosslinker, Qlinker, for studying conformational and structural changes in proteins and protein complexes using quantitative crosslinking mass spectrometry. Qlinkers are small and simple, amine-reactive molecules with an optimal extended distance of ~10 Å, which use MS2 reporter ions for relative quantification of Qlinker-modified peptides derived from different samples. We synthesized the 2-plex Q2linker and showed that the Q2linker can provide quantitative crosslinking data that pinpoints key conformational and structural changes in biosensors, binary and ternary complexes composed of the general transcription factors TBP, TFIIA, and TFIIB, and RNA polymerase II complexes.

    1. Biochemistry and Chemical Biology
    2. Stem Cells and Regenerative Medicine
    Alejandro J Brenes, Eva Griesser ... Angus I Lamond
    Research Article

    Human induced pluripotent stem cells (hiPSCs) have great potential to be used as alternatives to embryonic stem cells (hESCs) in regenerative medicine and disease modelling. In this study, we characterise the proteomes of multiple hiPSC and hESC lines derived from independent donors and find that while they express a near-identical set of proteins, they show consistent quantitative differences in the abundance of a subset of proteins. hiPSCs have increased total protein content, while maintaining a comparable cell cycle profile to hESCs, with increased abundance of cytoplasmic and mitochondrial proteins required to sustain high growth rates, including nutrient transporters and metabolic proteins. Prominent changes detected in proteins involved in mitochondrial metabolism correlated with enhanced mitochondrial potential, shown using high-resolution respirometry. hiPSCs also produced higher levels of secreted proteins, including growth factors and proteins involved in the inhibition of the immune system. The data indicate that reprogramming of fibroblasts to hiPSCs produces important differences in cytoplasmic and mitochondrial proteins compared to hESCs, with consequences affecting growth and metabolism. This study improves our understanding of the molecular differences between hiPSCs and hESCs, with implications for potential risks and benefits for their use in future disease modelling and therapeutic applications.